top of page
Browse by category
Search


Rani Therapeutics reveals data on semaglutide administered via the RaniPill capsule
Rani Therapeutics has revealed new pharmacokinetic (PK) and pharmacodynamic (PD) data from a preclinical study evaluating the oral...

FDA approves semaglutide to reduce the risk of worsening kidney disease and cardiovascular death
The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to...


Insurance coverage and type of employment shaping inequities in access to semaglutide
A study by Boston University School of Public Health (BUSPH) researchers has found that disparities in access to semaglutide, with rates...


STEP UP: Semaglutide 7.2mg achieves 20.7% weight loss and 18.7% regardless of treatment adherence
Novo Nordisk has announced headline results from the STEP UP study, a phase 3b trial in the global STEP programme, which revealed the...

Biomea Fusion announces first data on icovamenib-semaglutide combination study
Biomea Fusion has announced ‘compelling’ results from in vivo studies of icovamenib in combination with semaglutide. Icovamenib is an...


Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...

SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...


ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH
Results from part 1 of the ongoing Phase 3 ESSENCE trial - evaluating the effect of once-weekly subcutaneous semaglutide 2.4mg on liver...


Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD
A joint study by the University of Eastern Finland and Karolinska Institutet in Sweden has found that the GLP-1 agonists semaglutide and...


Helix model can predict 12-month weight loss response of semaglutide in diverse populations
Helix has unveiled new clinical research at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, featuring a novel...
Browse by tag





bottom of page